Patterns and resectability of colorectal cancer recurrences: outcome study within the COLOFOL trial

P. Hansdotter1,2,*, P. Scherman3,4, S. H. Petersen5, M. Mikalonis6, E. Holmberg7, M. Rizell3,8, P. Naredi3,9 and I. Syk1,2, on behalf of the COLOFOL study group

Abstract

Background: Improvements in surgery, imaging, adjuvant treatment, and management of metastatic disease have led to modification of previous approaches regarding the risk of recurrence and prognosis in colorectal cancer. The aims of this study were to map patterns, risk factors, and the possibility of curative treatment of recurrent colorectal cancer in a multimodal setting.

Methods: This was a cohort study based on the COLOFOL trial population of patients who underwent radical resection of stage II or III colorectal cancer. The medical files of all patients with recurrence within 5 years after resection of the primary tumour were scrutinized. Follow-up time was 5 years after the first recurrence. Primary endpoints were cumulative incidence, site, timing, and risk factors for recurrence, and rate of potentially curative treatment. A secondary endpoint was survival.

Results: Of 2442 patients, 471 developed recurrences. The 5-year cumulative incidence was 21.4 (95 per cent c.i. 19.5 to 23.3) per cent. The median time to detection was 1.1 years after surgery and 87.3 per cent were detected within 3 years. Some 98.2 per cent of patients who had potentially curative treatment were assessed by a multidisciplinary tumour board. A total of 47.8 per cent of the recurrences were potentially curatively treated. The 5-year overall survival rate after detection was 32.0 (95 per cent c.i. 27.9 to 36.3) per cent for all patients with recurrence, 58.6 (51.9 to 64.7) per cent in the potentially curatively treated group and 7.7 (4.8 to 11.5) per cent in the palliatively treated group.

Conclusion: Time to recurrence was similar to previous results, whereas the 21.4 per cent risk of recurrence was somewhat lower. The high proportion of patients who received potentially curative treatment, linked to a 5-year overall survival rate of 58.6 per cent, indicates that it is possible to achieve good results in recurrent colorectal cancer following multidisciplinary assessment.

Introduction

Colorectal cancer is the second most common cause of cancer-related mortality worldwide. Following surgery with curative intent, some 10–35 per cent of patients develop metachronous metastases. This range of reported recurrences reflects changes in the accuracy of preoperative staging, as well as different postoperative imaging between centres and time periods. These imaging techniques have improved markedly over the past two decades enabling earlier detection of metastases, making preoperative staging and postoperative surveillance examinations more accurate. Adjuvant chemotherapy has been adopted widely to prevent some recurrences. Considering all these factors, earlier estimates of the incidence of metachronous metastases and the likelihood of offering further treatment designed to achieve cure may now be inaccurate.

Follow-up programmes designed to detect recurrences that are possible to treat with curative intent are standard nowadays. Although large retrospective studies failed to prove any survival benefit from such programmes, small randomized trials that followed had some positive results, and subsequent systematic reviews and meta-analysis indicated survival benefit after more frequent examinations. Later large, randomized trials, such as COLOFOL, GILDA and FACS, could not establish a survival benefit from more frequent follow-up, although more recurrences in the high-frequency follow-up arm could be treated with curative intent. A Cochrane meta-analysis came to the same conclusion. The optimal design of a follow-up programme after curative resection for colorectal cancer is still unclear and proof of benefit resulting from intensive follow-up is lacking.
Whether a follow-up programme will lead to survival benefit depends on its ability to detect asymptomatic recurrences, and treat them with curative intent. The proportion of recurrences treated with curative intent varies markedly, reflecting differences in follow-up routines, multimodal treatment algorithms, and selection criteria for management of metastases. To optimize and individualize adjuvant therapies and design a surveillance programme with a positive effect on survival, it is important to know the risk factors and pattern of recurrences in a population of patients with colorectal cancer managed with modern multimodal treatment. This should include an understanding of patterns of recurrence amenable to treatment with curative intent. The aim of this study was to map the pattern of, and risk factors for, recurrences in a well defined population of patients with colorectal cancer who had undergone a multimodal treatment approach including curative surgery, and to evaluate the proportion of recurrences possible to treat with curative intent, based on the COLOFOL study cohort. Primary endpoints were the cumulative incidence, timing, and site of recurrence, risk factors for recurrence, and rate of potentially curatively treatment. Secondary endpoints were 5-year overall survival (OS) depending on recurrence site and mode of detection.

Methods

All patients in the study cohort were identified in the COLOFOL trial population. Detailed information on the COLOFOL trial study design and population has been reported previously. This study was not included in the original study plan. In summary, the COLOFOL trial enrolled patients who underwent radical surgery for stage II or III sporadic colorectal cancer between 2006 and 2010 at 24 sites in Sweden (15), Denmark (8), and Uruguay (1). Patients had to be aged 18–75 years with a life expectancy exceeding 2 years based on co-morbidity. The objective of the study was to compare overall and cancer-specific mortality according to the COLOFOL trial study group. Detailed information on the COLOFOL trial study group is available on request. All patients were followed prospectively for 5 years after resection.

Recurrence in mesenteric lymph nodes was defined as a local recurrence, whereas any recurrence in distant lymph nodes, including inguinal or para-aortic nodes, was defined as metastasis (M1). Anastomotic recurrences as well as retroperitoneal recurrences in the operative field of the bowel resection were considered local recurrences, whereas any other recurrence involving the peritoneum and/or omentum was defined as a peritoneal recurrence. Potentially curative treatment was defined as fulfilled resection or ablative treatment judged clinically as radical.

Time was measured from date of surgery to the first of the following events during 5-year follow-up: recurrence, death, or end of follow-up. The cumulative incidence of recurrence was computed using a competing-risk method, with death as a competing event and end of follow-up as a censoring event. Cumulative incidence reflects the probability of developing a recurrence during the time period, which also can be described as absolute risk during this interval. To facilitate readability, the term risk was used to describe the cumulative incidence during the study period.

Statistical analysis

All statistical analyses were carried out with Stata® version 16.1 (StataCorp, College Station, TX, USA). Figures for cumulative incidence in the presence of competing events were generated by means of the macro stcompet for Stata®. Both the cumulative incidence of recurrence and cumulative incidence of competing event (death) were calculated with 95% confidence interval. Hazard ratios (HRs) were calculated by cause-specific univariable and multivariable Cox proportional hazards regression to reflect the relative risk of recurrence between groups. In these analyses, death was a censoring event.

Secondary endpoints were 5-year OS according to recurrence site and mode of detection. OS was computed using the Kaplan–Meier method and group comparisons were made by univariable and multivariable Cox proportional hazards regression.

The proportional hazards assumption was tested with Schoenfeld’s residuals. When the assumption was violated (P < 0.050), the follow-up period was divided at 1 year into two intervals to achieve proportional hazards. All collected variables were included in the multivariable Cox regression analyses, and retained in the model if they were independently statistically significant or had P < 0.200 and a confounding effect (affected other HRs by more than 10 per cent). CEA was omitted from the analysis because there were too many missing values. P < 0.050 was considered statistically significant.

Results

A total of 2456 patients were randomized in the COLOFOL trial in Sweden and Denmark, of whom 14 were excluded as they did not fulfill the inclusion criteria or lacked information on recurrences. The present study involved 2442 patients, of whom 494 were registered with recurrences within 5 years after surgery. Following medical record review, 23 patients were reclassified without...
recurrence as no recurrences could be confirmed. Of these, eight patients were diagnosed with a new primary colorectal cancer, seven with primary lung cancer, one with a suspected mesenteric metastasis that proved to be benign, and one with primary ovarian cancer; in six patients, no obvious explanation could be established. A total of 471 patients were therefore confirmed to have recurrent disease and constituted the cohort of patients with recurrences.

Risk, site, and timing of recurrences

The total cumulative risk of recurrence was 21.4 (95 per cent c.i. 19.5 to 23.3) per cent. It was 13.4 (11.4 to 15.6) per cent in stage II and 30.7 (27.6 to 33.9) per cent in stage III disease (Table 1). No difference in risk of recurrence was noted between the Swedish and Danish cohorts (data not shown).

In total, 328 patients (69.6 per cent) developed a first recurrence at a single site, whereas 143 (30.4 per cent) developed recurrences at multiple sites. The most common site of first recurrence was liver (9.6 per cent), followed by lung (6.8 per cent).

Regarding lifestyle factors, daily smoking was an independent risk factor for recurrence. Postoperative adjuvant chemotherapy was given to 46.5 per cent of the patients (colon 52.6 per cent, rectum 35.2 per cent), with a reduction in recurrence risk of 38 per cent. Detailed information on risk factors is shown in Table 3 and Table S1.

Assessment and treatment

Of the 471 patients with recurrences, 418 (88.7 per cent) were assessed by multidisciplinary tumour board (MDT) because of the first recurrence and a total of 253 (53.7 per cent) were assessed as potentially curable. Of these, 225 (47.8 per cent) were finally treated with intent to achieve cure. Among these, 98.2 per cent were assessed in a MDT meeting compared with 80.1 per cent of those not curatively treated (P < 0.001). In patients with recurrences confined to one location, 207 of 328 (63.1 per cent) were potentially curatively treated, compared with 17 of 89 (19.1 per cent) with recurrences in two locations, and only 3 of 54 patients (5.6 per cent) with recurrences at three or more sites. The highest rate of potentially curative treatment was noted for liver metastases (122 of 148 patients with liver metastases only). In comparison, 53 of 89 patients (59.6 per cent) with lung metastases only, 15 of 23 (65.2 per cent) with peritoneal metastases only, and 21 of 38 (55.3 per cent) with isolated local recurrences received potentially curative treatment (Table 4). Of the 225 potentially curatively treated patients, 122 (54 per cent) received preoperative or postoperative adjuvant chemotherapy, 99 (44 per cent) had surgery alone, and data were missing for four patients. In the group of patients in whom recurrences were detected by scheduled examinations, 54.5 per cent were considered potentially curatively treated compared with 33.6 per cent of patients whose recurrences were detected by non-scheduled examinations (P < 0.001).

Survival

The 5-year OS rate for all patients with recurrence (calculated from the date of detection) was 32.0 (95 per cent c.i. 27.9 to 36.3) per cent. Sex did not influence survival. Patients with recurrences confined to a single organ had a significantly higher 5-year OS rate (40.2 (95 per cent c.i. 34.9 to 45.5) per cent) than those with two sites (20.4 (12.8 to 29.4) per cent) or multiple sites (2 (0.2 to 8.5) per cent) of recurrence. Patients with recurrences detected by scheduled examinations had a significantly higher 5-year OS rate than those with recurrence detected by symptoms or other

Table 1 Recurrences within 5 years after radical resection for stage II or III colorectal cancer, stratified by tumour stage and primary tumour location

| No. of patients | All | Liver only | Lung only | Other location | Multiple locations |
|----------------|-----|------------|-----------|----------------|-------------------|
| Overall        | 2442| 264 (18.3) | 32 (2.1)  | 90 (6.1)       | 21 (1.5)          |
| Stage II       |     |            |           |                |                   |
| T1–3 N1        | 657 | 62 (9.5)   | 17 (2.6)  | 67 (10.3)      | 25 (3.8)          |
| T1–3 N2        | 289 | 81 (28.2)  | 25 (8.8)  | 52 (18.1)      | 30 (10.4)         |
| T4 N1          | 83  | 42 (50.6)  | 17 (20.7) | 14 (16.9)      | 12 (14.5)         |
| T4 N2          | 94  | 40 (42.6)  | 18 (19.1) | 20 (21.3)      | 6 (6.4)           |
| Missing        | 4   | 0          | 0         | 0              | 0                 |
| Stage III      |     |            |           |                |                   |
| T1–3 N1        | 1127| 301 (26.8)| 96 (8.5)  | 64 (5.7)       | 9 (0.8)           |
| T1–3 N2        | 264 | 80 (30.3)  | 55 (20.8) | 19 (7.2)       | 10 (3.8)          |
| T4 N1          | 83  | 35 (42.2)  | 19 (22.9) | 15 (18.1)      | 9 (10.8)          |
| T4 N2          | 94  | 41 (43.7)  | 30 (32.3) | 17 (18.1)      | 6 (6.4)           |
| Missing        | 4   | 0          | 0         | 0              | 0                 |

Values in parentheses are percentage cumulative risks at 5 years.
Table 2 First recurrence within 5 years in patients who underwent primary radical surgery for stage II or III colorectal cancer, stratified by location

| Site of metastases | Liver | Lung | Peritoneum | Lymph nodes | Local | Other |
|--------------------|-------|------|------------|-------------|-------|-------|
| Liver              | 148 (6.1) | 23 (0.9) | 5 (0.2) | 11 (0.4) | 6 (0.2) | 1 (0.0) |
| Lung               | 23 (0.9) | 89 (3.6) | 0 (0) | 8 (0.3) | 7 (0.3) | 1 (0.0) |
| Peritoneum         | 5 (0.2) | 0 (0) | 23 (0.9) | 2 (0.1) | 16 (0.7) | 0 (0) |
| Lymph nodes        | 11 (0.4) | 8 (0.3) | 2 (0.1) | 25 (1.0) | 5 (0.2) | 2 (0.1) |
| Local recurrence   | 6 (0.2) | 7 (0.3) | 16 (0.7) | 5 (0.2) | 38 (1.6) | 1 (0.0) |
| Other              | 1 (0.0) | 1 (0.0) | 0 (0) | 2 (0.1) | 1 (0.0) | 5 (0.2) |
| >3 sites           | 41 (1.7) | 39 (1.6) | 26 (1.1) | 33 (1.4) | 21 (0.9) | 21 (0.9) |
| Total              | 235 (9.6) | 167 (6.8) | 72 (3.0) | 86 (3.5) | 94 (3.8) | 31 (1.3) |

Values in parentheses are percentages.

**Ad hoc analyses stratified by follow-up regimen**

Of the 471 patients who developed recurrences, a total of 248 were detected in the group randomized to high-intensity follow-up compared with 223 in the group randomized to low-intensity follow-up. The cumulative incidence of recurrence was similar in the high- and low-intensity groups: 23.1 (95 per cent c.i. 20.3 to 26.0) and 19.7 (17.3 to 22.2) per cent respectively. Median time to

---

reasons for examination (Fig. 2a). Survival is shown according to site of recurrence in Fig 2b. Patients with recurrences amenable to radical resection had a 7.6-fold higher 5-year OS rate than patients treated with palliative chemotherapy or best supportive care (58.6 versus 7.7 per cent) (Fig. 2c). HRs for 5-year mortality depending on mode of detection and site of recurrence (adjusted for age, sex, and follow-up regimen) are shown in Table 5.

---

Fig. 1 Time of detection of recurrences within 5 years following radical resection of stage II or III colorectal cancer, stratified by site of recurrence.

A) Stratified by 3-month periods after randomization; B) cumulative incidence for colonic cancer (including mortality as competing risk), and C) cumulative incidence for rectal cancer (including mortality as competing risk).
detection of recurrences was 1.39 years in the high-intensity and 1.03 years in the low-intensity groups (Fig. 3). A higher proportion of recurrences were detected by scheduled examinations in the high-intensity group (77.0% versus 59.4% per cent; \(P < 0.001\)).

Table 3 Risk factors for recurrence within 5 years following curative resection of stage II or III colorectal cancer

| No. of patients | No. of recurrences* (%) | Cumulative incidence of recurrence at 5 years (%) | Time period strata | Univariable Cox regression | Multivariable Cox regression (n = 2080)† |
|-----------------|------------------------|-----------------------------------------------|-------------------|--------------------------|----------------------------------------|
|                 |                        |                                               |                   | Hazard ratio†            | Hazard ratio                          |
| Smoker          |                        |                                               |                   | P                        | P                                       |
| No              | 1909                   | 352 (18.4)                                    | 20.4 (18.4, 22.5) | 1.00 (reference)         | 1.00 (reference)                       |
| Yes, occasionally | 24                    | 8 (33.3)                                      | 64.5 (19.6, 69.6) | 1.92 (0.95, 3.86)        | 1.92 (0.90, 4.08)                      |
| Yes, daily       | 371                    | 87 (23.4)                                     | 36.5 (21.7, 33.1) | 1.54 (1.06, 2.69)        | 1.46 (1.13, 1.89)                      |
| Missing          | 138                    | 24 (17.4)                                     |                   |                          |                                        |
| Alcohol, daily intake |                |                                               |                   |                          |                                        |
| None            | 1541                   | 324 (21.0)                                    | 22.4 (20.2, 24.7) | 1.00 (reference)         | 1.00 (reference)                       |
| <3 drinks       | 505                    | 82 (16.2)                                     | 64.5 (19.6, 69.6) | 0.76 (0.59, 0.96)        | 0.76 (0.52, 0.96)                      |
| ≥3 drinks       | 110                    | 21 (19.1)                                     | 36.5 (21.7, 33.1) | 91 (0.58, 1.41)          | 0.89 (0.56, 1.41)                      |
| Missing          | 286                    | 44 (15.4)                                     |                   |                          |                                        |
| BMI (kg/m²)     |                        |                                               |                   |                          |                                        |
| <18.5           | 56                     | 18 (32.1)                                     | 33.3 (22.3, 47.7) | 1.83 (1.13, 2.95)        | 1.59 (0.96, 2.63)                      |
| 18.5–24.9       | 1088                   | 208 (19.1)                                    | 32.4 (26.8, 38.9) | 1.21 (0.72, 1.31)        | 0.89 (0.63, 1.24)                      |
| 25.0–29.9       | 932                    | 179 (19.2)                                    | 20.3 (15.8, 26.0) | 0.97 (0.72, 1.31)        | 0.84 (0.56, 1.41)                      |
| ≥35.0           | 77                     | 12 (15.6)                                     | 15.9 (0.4, 26.4)  | 0.77 (0.44, 1.41)        | 0.86 (0.48, 1.56)                      |
| Missing          | 3                      | 0 (0)                                         |                   |                          |                                        |
| Diabetes        |                        |                                               |                   |                          |                                        |
| No              | 2224                   | 416 (18.7)                                    | 20.7 (18.8, 22.7) | 1.00 (reference)         | 1.00 (reference)                       |
| Yes             | 218                    | 55 (25.2)                                     | 28.2 (22.0, 35.8) | 1.36 (1.02, 1.80)        | 1.51 (1.11, 2.06)                      |
| T category      |                        |                                               |                   |                          |                                        |
| T1–3            | 2090                   | 362 (17.3)                                    | 19.4 (17.5, 21.5) | 1.00 (reference)         | 1.00 (reference)                       |
| T4              | 347                    | 109 (31.4)                                    | 33.5 (28.3, 39.4) | 2.01 (1.62, 2.49)        | <0.001 2.01 (1.58, 2.56)               |
| Missing          | 5                      | 0 (0)                                         |                   |                          |                                        |
| Lymph node ratio‡ |                        |                                               |                   |                          |                                        |
| Negative        | 1287                   | 153 (11.9)                                    | 12.9 (11.0, 15.1) | 1.00 (reference)         | 1.00 (reference)                       |
| <0.1            | 426                    | 72 (16.9)                                     | 20.4 (16.0, 25.9) | 0.77 (0.46, 1.29)        | 0.322 1.17 (0.67, 2.03)                |
| 0.1–0.25        | 351                    | 98 (27.9)                                     | 32.4 (26.8, 38.9) | 1.21 (0.73, 1.95)        | 0.434 1.60 (0.95, 2.69)                |
| >0.25           | 337                    | 140 (41.5)                                    | 43.8 (38.1, 49.9) | 3.81 (2.71, 5.35)        | <0.001 4.69 (3.6, 6.94)                |
| Missing          | 41                     | 8 (19.5)                                      |                   |                          |                                        |
| Location        |                        |                                               |                   |                          |                                        |
| Rectum          | 857                    | 207 (24.2)                                    | 27.4 (23.9, 31.2) | 1.00 (reference)         | 1.00 (reference)                       |
| Colon           | 1585                   | 264 (16.7)                                    | 18.3 (16.3, 20.5) | 0.65 (0.55, 0.78)        | <0.001 0.60 (0.49, 0.74)               |
| Adjuvant treatment (postoperative) | |                                               |                   |                          |                                        |
| No              | 1306                   | 216 (16.5)                                    | 18.2 (15.9, 20.7) | 1.00 (reference)         | 1.00 (reference)                       |
| Yes             | 1136                   | 255 (22.4)                                    | 25.0 (22.2, 28.1) | 1.40 (1.17, 1.68)        | <0.001 1.40 (1.17, 1.68)               |

Values in parentheses are *percentages and †95 per cent confidence intervals. The following statistically non-significant or non-confounding risk factors were omitted from the multivariable analysis: age, sex, history of myocardial infarction, pulmonary disease, elective or emergency resection of primary tumour, severe postoperative complication after resection of primary lesion, postoperative blood transfusion. Proportional hazards assumption not fulfilled (tested with Schoenfeld’s residuals), so variable fractioned in two time periods.

Table 4 Proportion of curatively treated first recurrences within 5 years in patients primarily radically operated for colorectal cancer stage II and III, stratified by location

| Site of metastases | Liver | Lung | Peritoneum | Lymph nodes | Local recurrence | Other |
|--------------------|-------|------|------------|-------------|------------------|-------|
| Liver              | 112   | 6    | 1          | 2           | 1                | 0     |
| Lung               | 6     | 53   | 0          | 0           | 0                | 2     |
| Peritoneum         | 1     | 0    | 15         | 0           | 2                | 3     |
| Lymph nodes        | 2     | 0    | 6          | 2           | 2                | 2     |
| Local recurrence   | 1     | 2    | 3          | 2           | 21               | 21    |
| Other              | 0     | 0    | 0          | 0           | 0                | 0     |
| >3 sites           | 1     | 1    | 0          | 0           | 0                | 1     |
| Total              | 123   | 62   | 19         | 10          | 29               | 1     |

The proportion of detected recurrences that it was possible to treat potentially curatively was also similar in the two groups (49.2% per cent with high- and 46.2% per cent with low-intensity follow-up). The 5-year OS rate, calculated from the date of detection...
of recurrences, was better in the high-intensity group: 37.8 (95 per cent c.i. 31.8 to 43.9) versus 25.6 (20.0 to 31.4) per cent; however, this difference did not reach statistical significance in the multivariable analysis (Table 5).

Discussion

The recurrence risks of 13.4 per cent in stage II and 30.7 per cent in stage III colorectal cancer are lower than most earlier estimations, but in line with other recent studies, probably reflecting improvements in surgical technique, neoadjuvant treatment, imaging techniques, and structured work-up. Another important factor is the effect of adjuvant chemotherapy as standard care in high-risk stage II and stage III disease. The efficacy of adjuvant treatment in the present study was underlined in the adjusted multivariable analyses, which showed a 38 per cent decreased risk of recurrence. This was slightly higher than previous estimations, which might be due in part to the relatively high proportion of patients receiving this treatment in the present study.

Risk factors associated with recurrence were largely in agreement with previous reports, although the pronounced impact of high LNR (ratio of positive lymph nodes exceeding 0.25) is not widely recognized and merits consideration in the choice of adjuvant therapy. Smoking is a well known risk factor for developing cancer, including colorectal cancer; although described previously as a risk factor for increased risk of recurrence, this has not been reported widely. A finding of interest was that a moderate daily intake of alcohol was associated with a decreased risk of recurrent disease. This requires confirmation in a separate cohort.

It was possible to deliver potentially curative treatment in almost half of the patients with recurrences. Three-quarters of the patients with metastases confined to the liver only were potentially curatively treated, a higher proportion than reported previously, indicating an absolute survival benefit in this group. Compared with earlier reports, potentially curative treatments were also undertaken in higher proportions of patients also for isolated lung metastases (59.6 per cent), isolated peritoneal metastases (65.2 per cent), and isolated local recurrences (55.3 per cent). Among those with recurrences involving lymph nodes, treatment with curative

---

![Fig. 2](https://example.com/fig2.png)

**Fig. 2** Overall survival from date of first recurrence to death or 5-year follow-up, following radical resection of stage II or III colorectal cancer. Stratified by A) mode of recurrence detection, B) site of recurrence, and C) possible treatment. *Data on mode of detection missing for four patients. BSC, best supportive care.
Table 5: Five-year overall survival after date of first recurrence in 471 patients following stage II or III curative resection of colorectal cancer

| Recurrence site | Proportion of patients who died | 5-year OS (%) | Time period strata | Univariable Cox regression | Multivariable Cox regression |
|-----------------|---------------------------------|---------------|--------------------|----------------------------|-----------------------------|
| Liver           | 79 of 148                       | 46.6 (38.4, 54.4) |                    | 1.00 (reference)           | 1.00 (reference)            |
| Lung            | 49 of 89                        | 44.9 (34.4, 54.9) |                    | 1.01 (0.71, 1.44)          | 1.24 (0.85, 1.81)           |
| Multiple sites  | 124 of 143                      | 13.3 (8.3, 19.4)  |                    | 2.85 (2.14, 3.78)          | <0.001 2.60 (1.94, 3.49)    |
| Other sites     | 68 of 91                        | 25.3 (16.9, 34.5) |                    | 1.88 (1.36, 2.60)          | <0.001 1.76 (1.25, 2.49)    |

| Time from surgery to recurrence (per year) | Hazard ratio | P       | Hazard ratio | P       |
|-------------------------------------------|--------------|---------|--------------|---------|
| Not included                               |              |         |              |         |
| Time from surgery to recurrence by group (years) |              |         |              |         |
| <1                                        | 1.00 (reference) | 0.078   | 1.00 (reference) | 0.94    |
| 1 to <2                                   | 1.01 (0.78, 1.31) | 0.94    | 1.00 (reference) | 0.078   |
| 2 to <3                                   | 0.80 (0.58, 1.10) | 0.17    | 1.00 (reference) | 0.80 (0.58, 1.10) | 0.17 |
| 3 or >                                    | 0.69 (0.47, 1.00) | 0.052   | 1.00 (reference) | 0.69 (0.47, 1.00) | 0.052 |

Mode of recurrence detection:

- Scheduled: 195 of 231, 39.2 (33.9, 44.6)
- Symptom: 95 of 111, 14.3 (8.6, 21.5)
- Other: 26 of 35, 25.7 (12.8, 40.8)

| Follow-up regimen | Hazard ratio | P       | Hazard ratio | P       |
|-------------------|--------------|---------|--------------|---------|
| Low intensity     | 1.00 (reference) | 0.078   | 1.00 (reference) | 0.94    |
| High intensity    | 0.72 (0.56, 0.89) | 0.003   | 0.80 (0.64, 1.01) | 0.058   |

Sex:

- M: 185 of 271, 31.7 (26.2, 37.3)
- F: 135 of 200, 35.2 (26.1, 39.0)

| Age at recurrence (per 10 years) | Hazard ratio | P       | Hazard ratio | P       |
|----------------------------------|--------------|---------|--------------|---------|
| 0–5                             | 1.00 (reference) | 0.078   | 1.00 (reference) | 0.94    |
| 60–69                           | 1.22 (1.06, 1.40) | 0.006   | 1.29 (1.11, 1.50) | 0.001   |
| >70                             | Not included  |         |              |         |

Primary site:

- Rectum: 125 of 207, 39.6 (32.9, 46.1)
- Colon: 195 of 264, 26.1 (21.0, 31.6)

Values in parentheses are 95 per cent confidence intervals. OS, overall survival. Statistically non-significant or non-confounding risk factors were omitted from the multivariable analysis. *Proportional hazards assumption not fulfilled (tested with Schoenfeld’s residuals), so variable fractioned in two time periods.

Fig. 3 Cumulative incidence of recurrences following radical resection of stage II or III colorectal cancer stratified by follow-up regimen

The intent was considerably less frequent and possible in only 11 per cent if combined with other sites of recurrence. The high rate of assessment in MDT meetings may have been crucial in achieving these figures. An increased rate of metastases being allocated to resection with curative intent by assessment of organ specialists has been shown for liver metastases and recurrences of colorectal cancer in general. Improved diagnostics and chemotherapy strategies have also been proven for different diagnoses by MDT assessment.

Patients with recurrences detected by scheduled examinations had a better prognosis than those with recurrences detected by symptoms. This is probably affected by lead time bias as these recurrences are detected earlier but might also be associated with the higher proportion of potentially curatively treated recurrences in this group. If so, it indicates a benefit of the follow-up programme, although examinations were quite limited in both study arms. The high HR (4.60) for mortality associated with recurrences detected by symptoms during the first year indicates that this group consisted of fast-growing aggressive tumours, possibly with a poor chance of long-term survival. Although interval cancer was an independent risk factor for mortality also in the later time period, the impact was much less (HR 1.55). Recurrence of colonic cancer was an independent risk factor for mortality compared with rectal cancer (HR 1.34), possibly related to the proportion of tumours with microsatellite instability (MSI) in the colon, but no data were available on MSI status.

Patients who received potentially curative treatment had a 5-year OS rate of 58.6 per cent, similar to or slightly higher than earlier results, indicating that the increased rate of treatment translated into cure. This is further supported by the 5-year OS rate of 32.0 per cent in the whole group of patients with recurrences. The fact that patients aged over 75 years were not included in the study is likely to have influenced these survival
figures. Although outcome was worse for patients whose recurrences were detected within 1 year, the 5-year OS rate in this group was still 29.4 per cent, so early recurrences should not be regarded as a contraindication to treatment with curative intent. These data indicate that structured follow-up, although quite limited, combined with MDT assessment can provide good results in recurrent colorectal cancer.

A limited number of recurrences were detected after the scheduled follow-up-time of 3 years, suggesting that this duration of follow-up is sufficient. As expected, recurrences were detected earlier in the high-intensity group during the period of scheduled examinations. This is also reflected by a higher rate of recurrences detected by scheduled examinations in this group. A larger number of recurrences were detected in the high-intensity group after the 3 years of scheduled follow-up, which explains the longer median time to detection of all recurrences in this group. The reason why more recurrences were detected in this group after the period of scheduled examinations is elusive.

The 5-year OS rate after first recurrence was higher in the high-intensity group (calculated from date of detection), probably reflecting lead time bias considering that recurrences were detected earlier on as a result of more frequent examinations. In the multivariable analysis, the HR did not reach statistical significance. Earlier detection might be associated with smaller, treatable recurrences. As more recurrences were detected after 3 years in the group with high-intensity follow-up, this might also have been a factor, as these late recurrences probably have a more favourable prognosis, supported by the multivariable analysis showing a HR of 0.84 per year. In the main study, including the total COLOFOL trial population, no difference in overall or colorectal cancer-specific mortality was noted between the randomization groups, calculated from date of operation of the primary tumour (P = 0.43 and P = 0.52)\(^4\).

The major strength of this study was that it was based on a prospectively created data set of recurrences in the framework of a randomized trial with scheduled follow-up, all medical files were scrutinized for detailed data on every recurrence, work-up at diagnosis involved colonoscopy and high-resolution multislice CT of liver and lungs, and a high proportion of recurrences were assessed in MDT meetings. The generalizability is therefore likely to be good, based on an inclusion rate of 56.4 per cent in the main study, and good resemblance between the study population and eligible non-randomized patients according to a drop-out analysis\(^26\). The cut-off age of 76 years or older for inclusion in the study may also have influenced the proportion of patients treated with curative intent for recurrences.

The main limitation is that scheduled follow-up was limited to 3 years. Thus, recurrences detected between 3 and 5 years after primary surgery were not detected by scheduled examinations but by symptoms or a local follow-up protocol. There is a risk of underestimation of recurrences as a result. As follow-up in the study was 5 years, recurrences that occurred later than 5 years after operation were not registered and the total risk of recurrences might be higher than the 5-year risk presented.

Despite radical primary operation and a high proportion of patients treated with adjuvant chemotherapy, 21.4 per cent of patients with stage II or III colorectal cancer had recurrences. Structured follow-up, although limited, and meticulous MDT review, resulted in a high proportion of recurrences being amenable to potentially curative treatment with subsequent long-term survival.

Collaborators

Steering Committee: P. Wille-Jørgensen (Bispebjerg University Hospital, Copenhagen, Denmark) (Principal Investigator); E. Horváth-Puhó, S. Laurberg (Aarhus University Hospital, Aarhus, Denmark); the late L. Pahlman (Uppsala Academic Hospital, Uppsala, Sweden); A. Renehan (University of Manchester, Manchester, UK); K. Smedø (Vasteras Hospital, Vasteras, Sweden); I. Sjök (Skåne University Hospital, Malmö, Sweden). Denmark, investigation group: H. Christensen (Aarhus University Hospital, Aarhus); J. D. Nielsen (Aalborg University Hospital, Aalborg); P. Jess (Hillerød Hospital, Hillerød); A. G. Pedersen (Randers Hospital, Randers); M. R. Madsen (Herning Hospital, Herning); P. V. Andersen (Svendborg Hospital, Svendborg); E. Østergaard (Viborg Hospital, Viborg), Sweden, investigation group: P. Hansdotter Andersson (Skåne University Hospital, Malmö); J. Bengtsson (Sahlgrenska Hospital, Gothenburg); M. Bragmark (Danderyd University Hospital, Danderyd); P. Buchwald (Helsingborg Hospital, Helsingborg); E. Engvall (Karolinska University Hospital, Huddinge, Stockholm); F. Farahnak (Södersjukhuset, Stockholm); J. Folkesson (Uppsala Academic Hospital, Uppsala); M. Goldinger (St Görans Hospital, Stockholm); R. Heumann (Mora Hospital, Mora); K. Lindberg (Södertälje Hospital, Södertälje); A. Martling (Karolinska University Hospital Solna, Stockholm); P. Nasvall (Sunderby Hospital, Luleå); J. Ottosson (Kristianstad Hospital, Kristianstad); B. Sandén (Norrland University Hospital, Umeå), Uruguay, investigation group: C. Barberousse (Maciel University Hospital, Montevideo).

Acknowledgements

P.H. and P.S. contributed equally to this work.

Disclosure. The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424
2. Malakorn S, Ouchi A, Hu CY, Sandhu I, Dasari A, You YN et al. Tumor sidedness, recurrence, and survival after curative resection of localized colon cancer. Clin Colorectal Cancer 2021; 20: e53–e60
3. Galandik S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ Jr, Pemberton JH et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27–32
4. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colon cancer in a well defined population. Br J Surg 2006; 93: 1115–1122
5. Gunawardene A, Desmond B, Shekouh A, Larsen P, Dennett E. Disease recurrence following surgery for colorectal cancer: five-year follow-up. N Z Med J 2018; 131: 51–58
6. van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijisman JH et al. Patterns of metachronous
metastases after curative treatment of colorectal cancer. Cancer Epidemiol 2014;38:448–454
7. Osterman E, Glímelius B. Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum 2018;61:1016–1025
8. Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glímelius B. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 2015;54:5–16
9. Jonker DJ, Spithoff K, Maroun J. Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) 2011;23:314–322
10. Meyers BM, Cosby R, Quereshy F, Jonker D. Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a Cancer Care Ontario systematic review. Clin Oncol (R Coll Radiol) 2017;29:459–465
11. Kievit J, Bruinvels DJ. Detection of recurrence after surgery for colorectal cancer. Eur J Cancer 1995;31A:1222–1225
12. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002;CD002200
13. Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813
14. Wille-Jørgensen P, Syk I, Smedh K, Laurberg S, Nielsen DT, Petersen SH et al.; COLOFOL Study Group. Effect of more versus less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA 2018;319:2095–2103
15. Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G et al.; GILDA working group. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2–C colorectal carcinoma. Ann Oncol 2016;27:274–280
16. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A et al.; FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014;311:263–270
17. Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2016; (11)CD002200
18. Kodeda K, Derwinger K, Gustavsson B, Nordgren S. Local recurrence of rectal cancer: a population-based cohort study of diagnosis, treatment and outcome. Colorectal Dis 2012;14:e230–e237
19. Simmonds PC, Primrose JN, Colquitt LJ, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982–999
20. Hansdotter Andersson P, Wille-Jørgensen P, Horvath-Puho E, Petersen SH, Martling A, Sorensen HT et al. The COLOFOL trial: study design and analysis of the study population with the source cancer population. Clin Epidemiol 2016;8:15–21
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706
22. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P et al. Impact of recurrence and salvage surgery on survival after multidisciplinary treatment of rectal cancer. J Clin Oncol 2017;35:2631–2638
23. Shah MA, Renfro LA, Allegra CJ, Andre T, de Gramont A, Schmoll HJ et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the Adjuvant Colon Cancer End Points (ACCENT) database. J Clin Oncol 2016;34:843–853
24. Walter V, Jansen L, Hoffmeister M, Ulrich A, Chang-Claude J, Brenner H. Smoking and survival of colorectal cancer patients: population-based study from Germany. Int J Cancer 2015;137:1433–1445
25. Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases—have we reached our (non-resectable) limit? J Surg Oncol 2010;102:922–931
26. Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y et al. Outcome of patients with colorectal liver metastasis: analysis of 1613 consecutive cases. Ann Surg Oncol 2012;19:2860–2868
27. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405–1410
28. Elferink MA, de Jong KP, Klaase JM, Siemerink EJ, de Wilt JH. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis 2015;30:205–212
29. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–3683
30. Zellweger M, Abdelmour-Berchtold E, Krueger T, Ris HB, Perentes JY, Gonzalez M. Surgical treatment of pulmonary metastasis in colorectal cancer patients: current practice and results. Crit Rev Oncol Hematol 2018;127:105–116
31. Kodeda K, Nathanaelsson L, Jung B, Olsson H, Jestin P, Sjovall A et al. Population-based data from the Swedish Colon Cancer Registry. Br J Surg 2013;100:1100–1107
32. Amelung FJ, Consten ECJ, Siensema PD, Tanis PJ. A population-based analysis of three treatment modalities for malignant obstruction of the proximal colon: acute resection versus stent or stoma as a bridge to surgery. Ann Surg Oncol 2016;23:3660–3668
33. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Loddick F, Hartmann JT et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38–47
34. Segelman J, Singnomklao T, Hellborg H, Martling A. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis 2009;11:768–774
35. Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 2020;20:73
36. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, Te Velde A, Dezutter-Dambuyant C. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915–924